These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 21445582)

  • 1. Roles for biological membranes in regulating human immunodeficiency virus replication and progress in the development of HIV therapeutics that target lipid metabolism.
    Haughey NJ; Tovar-y-Romo LB; Bandaru VV
    J Neuroimmune Pharmacol; 2011 Jun; 6(2):284-95. PubMed ID: 21445582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The functional roles of lipid rafts in T cell activation, immune diseases and HIV infection and prevention.
    Luo C; Wang K; Liu DQ; Li Y; Zhao QS
    Cell Mol Immunol; 2008 Feb; 5(1):1-7. PubMed ID: 18318989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipids and membrane microdomains in HIV-1 replication.
    Waheed AA; Freed EO
    Virus Res; 2009 Aug; 143(2):162-76. PubMed ID: 19383519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure.
    Nieto-Garai JA; Glass B; Bunn C; Giese M; Jennings G; Brankatschk B; Agarwal S; Börner K; Contreras FX; Knölker HJ; Zankl C; Simons K; Schroeder C; Lorizate M; Kräusslich HG
    Front Immunol; 2018; 9():1983. PubMed ID: 30233582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of lipids in virus replication.
    Lorizate M; Kräusslich HG
    Cold Spring Harb Perspect Biol; 2011 Oct; 3(10):a004820. PubMed ID: 21628428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV: a raft-targeting approach for prevention and therapy using plant-derived compounds (review).
    Verma SP
    Curr Drug Targets; 2009 Jan; 10(1):51-9. PubMed ID: 19149536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of cellular cholesterol inhibits membrane binding and higher-order multimerization of human immunodeficiency virus type 1 Gag.
    Ono A; Waheed AA; Freed EO
    Virology; 2007 Mar; 360(1):27-35. PubMed ID: 17095032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus maturation as a new HIV-1 therapeutic target.
    Adamson CS; Salzwedel K; Freed EO
    Expert Opin Ther Targets; 2009 Aug; 13(8):895-908. PubMed ID: 19534569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus assembly and plasma membrane domains: which came first?
    Kerviel A; Thomas A; Chaloin L; Favard C; Muriaux D
    Virus Res; 2013 Feb; 171(2):332-40. PubMed ID: 22989508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells.
    Popik W; Alce TM; Au WC
    J Virol; 2002 May; 76(10):4709-22. PubMed ID: 11967288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy.
    Raulin J
    Prog Lipid Res; 2002 Jan; 41(1):27-65. PubMed ID: 11694268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of cellular proteins in the life cycle of human immunodeficiency virus].
    Bukrinskaia AG
    Vopr Virusol; 2009; 54(1):4-7. PubMed ID: 19253722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virus entry, assembly, budding, and membrane rafts.
    Chazal N; Gerlier D
    Microbiol Mol Biol Rev; 2003 Jun; 67(2):226-37, table of contents. PubMed ID: 12794191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus type 1 Nef protein modulates the lipid composition of virions and host cell membrane microdomains.
    Brügger B; Krautkrämer E; Tibroni N; Munte CE; Rauch S; Leibrecht I; Glass B; Breuer S; Geyer M; Kräusslich HG; Kalbitzer HR; Wieland FT; Fackler OT
    Retrovirology; 2007 Oct; 4():70. PubMed ID: 17908312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetraspanins, Another Piece in the HIV-1 Replication Puzzle.
    Suárez H; Rocha-Perugini V; Álvarez S; Yáñez-Mó M
    Front Immunol; 2018; 9():1811. PubMed ID: 30127789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host factors mediating HIV-1 replication.
    Friedrich BM; Dziuba N; Li G; Endsley MA; Murray JL; Ferguson MR
    Virus Res; 2011 Nov; 161(2):101-14. PubMed ID: 21871504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid rafts and HIV-1: from viral entry to assembly of progeny virions.
    Campbell SM; Crowe SM; Mak J
    J Clin Virol; 2001 Oct; 22(3):217-27. PubMed ID: 11564586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early events of HIV-1 infection: can signaling be the next therapeutic target?
    Jones KL; Smyth RP; Pereira CF; Cameron PU; Lewin SR; Jaworowski A; Mak J
    J Neuroimmune Pharmacol; 2011 Jun; 6(2):269-83. PubMed ID: 21373988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stages of HIV replication and targets for therapeutic intervention.
    Tözsér J
    Curr Top Med Chem; 2003; 3(13):1447-57. PubMed ID: 14529520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic tradeoffs in the raft-mediated entry of human immunodeficiency virus type 1 into cells.
    Lim KI; Yin J
    Biotechnol Bioeng; 2006 Feb; 93(2):246-57. PubMed ID: 16136590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.